In 2021, Moncef Slaoui earned $938.36K in total compensation at Vaxcyte, Inc., including $574.80K salary and $363.56K bonus. Led Vaxcyte, Inc. as CEO for 3 years.
Compensation History
Annual executive compensation data for Moncef Slaoui, including salary, bonuses, and stock awards.
Year
2021
Total Compensation
$938.36K
Salary
$574.80K
Bonus
$363.56K
Other
$0.00
Salary
$574.80KBoard Justification
The compensation program aims to attract, retain and reward highly-qualified executives while providing incentives that motivate and reward for achievement of key performance goals, aligning executives’ interests with those of stockholders.
Bonus
$363.56KBoard Justification
The annual performance-based cash bonus awards provide incentive compensation that is specifically designed to motivate our executive officers to achieve pre-established, company-wide priorities set by the Compensation Committee and to reward them for results and achievements in a given year.
Other Compensation
$0.00Board Justification
No other compensation was provided outside of salary, bonus, and stock options.
Restricted Stock
Board Justification
No stock was vested in 2021 as the focus is on cash compensation and performance-based bonuses.
Performance Metrics
The performance metrics for the CEO's compensation were based on the achievement of corporate goals related to the VAX-24 program and other pipeline programs.
Moncef Slaoui
Ex-CEO of Vaxcyte, Inc.
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
CEO of Vaxcyte, Inc. for
3 years 8 months (Jul 2017 - Mar 2021)
Previous Experience
Former employee of GlaxoSmithKline, extensive experience in vaccine development and biotechnology.
Other Vaxcyte, Inc. CEOs
Holdings
Track Moncef Slaoui's stock holdings and portfolio value over time.
Insider Trading
Moncef Slaoui's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Moncef Slaoui with competitor CEOs and industry peers.